Printer Friendly

ThromboGenics' Jetrea recommended for reimbursement by UK's National Institute for Health and Care Excellence.

M2 EQUITYBITES-September 4, 2013-ThromboGenics' Jetrea recommended for reimbursement by UK's National Institute for Health and Care Excellence(C)2013 M2 COMMUNICATIONS http://www.m2.com

Integrated biopharmaceutical company, ThromboGenics' new Jetrea (ocriplasmin) treatment is recommended for reimbursement by the UK's National Institute for Health and Care Excellence in its Final Appraisal Determination, it was reported yesterday.

According to the company, the reimbursement will be conducted within the National Health Service in England and Wales.

Jetrea treats vitreomacular traction and macular hole and was recommended for reimbursement, for treatment of patients showing symptoms of metamorphopsia, whose impact is considered severe and distressing, and equal to loss of two lines in visual acuity.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:4EUUK
Date:Sep 4, 2013
Words:122
Previous Article:Crestview Partners wraps up DS Waters takeover.
Next Article:News Corp sells Dow Jones Local Media Group to Fortress Investment.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters